OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
-1.83%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$265M
AUM Growth
+$265M
(-8%)
Cap. Flow
-$2.11M
Cap. Flow
% of AUM
-0.8%
Top 10 Holdings %
Top 10 Hldgs %
61.75%
Holding
38
New
7
Increased
6
Reduced
4
Closed
10
Top Buys
| 1 |
IMA
ImageneBio, Inc. Common Stock
IMA
|
$11.3M |
| 2 |
Design Therapeutics
DSGN
|
$7.48M |
| 3 |
CNTB
Connect Biopharma
CNTB
|
$6.91M |
| 4 |
Merus
MRUS
|
$4.18M |
| 5 |
Edgewise Therapeutics
EWTX
|
$4.06M |
Top Sells
| 1 |
Celldex Therapeutics
CLDX
|
$9.89M |
| 2 |
CALT
Calliditas Therapeutics AB American Depositary Shares
CALT
|
$6.72M |
| 3 |
FibroGen
FGEN
|
$5.42M |
| 4 |
Kiniksa Pharmaceuticals
KNSA
|
$5.22M |
| 5 |
Kura Oncology
KURA
|
$4.9M |
Sector Composition
| 1 | Healthcare | 95.99% |
| 2 | Financials | 1.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMAB
1
I-MAB
IMAB
$340M
| $25.7M | 9.68% | 530,050 +75,500 | +17% | +$3.66M |
|
2
Curis
CRIS
$20.9M
| $24.1M | 9.08% | 2,128,400 -71,600 | -3% | -$810K |
|
3
Apellis Pharmaceuticals
APLS
$3.48B
| $23.5M | 8.86% | 548,374 | – | – |
|
4
4D Molecular Therapeutics
FDMT
$288M
| $16.4M | 6.18% | 378,288 +511 | +0.1% | +$22.2K |
|
|
XLRN
5
DELISTED
Acceleron Pharma Inc.
XLRN
| $15.2M | 5.74% | 112,363 | – | – |
|
6
Gossamer Bio
GOSS
$562M
| $13.1M | 4.92% | 1,413,138 -150,000 | -10% | -$1.39M |
|
7
Arvinas
ARVN
$568M
| $11.8M | 4.44% | 178,500 | – | – |
|
|
8
Celldex Therapeutics
CLDX
$1.47B
| $11.6M | 4.36% | 561,398 -480,000 | -46% | -$9.89M |
|
|
IMA
9
ImageneBio, Inc. Common Stock
IMA
$150M
| $11.3M | 4.26% | +400,000 | New | +$11.3M |
|
10
Arcus Biosciences
RCUS
$1.13B
| $11.2M | 4.23% | 400,000 +100,000 | +33% | +$2.81M |
|
11
Avidity Biosciences
RNA
$5.99B
| $9.74M | 3.67% | 446,641 +16,600 | +4% | +$362K |
|
12
Dyne Therapeutics
DYN
$1.92B
| $9.06M | 3.41% | 583,649 +102,111 | +21% | +$1.59M |
|
13
PMV Pharmaceuticals
PMVP
$74.2M
| $8.22M | 3.1% | 250,000 | – | – |
|
|
CCXI
14
DELISTED
ChemoCentryx, Inc.
CCXI
| $7.69M | 2.9% | 150,076 -75,000 | -33% | -$3.84M |
|
|
15
Design Therapeutics
DSGN
$315M
| $7.48M | 2.82% | +250,000 | New | +$7.48M |
|
|
CNTB
16
Connect Biopharma
CNTB
$115M
| $6.91M | 2.6% | +373,492 | New | +$6.91M |
|
17
Taysha Gene Therapies
TSHA
$797M
| $6.51M | 2.45% | 320,440 | – | – |
|
18
Cardiff Oncology
CRDF
$140M
| $6.02M | 2.27% | 650,000 | – | – |
|
|
NGM
19
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $5.81M | 2.19% | 200,000 +124,773 | +166% | +$3.63M |
|
20
Revolution Medicines
RVMD
$7.1B
| $5.79M | 2.18% | 126,136 | – | – |
|
|
KRON
21
DELISTED
Kronos Bio
KRON
| $4.28M | 1.61% | 146,173 | – | – |
|
|
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.2M | 1.58% | 680,036 | – | – |
|
|
23
Merus
MRUS
$4.98B
| $4.18M | 1.57% | +200,000 | New | +$4.18M |
|
24
MoonLake Immunotherapeutics
MLTX
$3.54B
| $4.08M | 1.54% | 400,000 | – | – |
|
|
25
Edgewise Therapeutics
EWTX
$1.51B
| $4.06M | 1.53% | +125,000 | New | +$4.06M |
|